Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1653 1656
This examiner grants 52% of resolved cases
Susan Emily Fernandez is an examiner in Tech Center 1600 and Art Unit 1651, with 562 resolved cases. Her allowance rate is 52.5 percent. This rate indicates that about half of the cases she resolves result in a patent grant. The 52.5 percent allowance rate suggests a balanced environment where success depends on the technical merits and the quality of the prosecution strategy.
The interview lift is 60.8 percent. This is an exceptionally high lift, suggesting that interviews are an extremely powerful tool for overcoming rejections. Given the 52.5 percent allowance rate, conducting an interview appears to be a critical step for practitioners looking to improve their chances of success. For the 562 resolved cases, the 60.8 percent lift is the most significant strategic lever available.
The median days to allowance is 1364. This timeline provides a benchmark for the duration of the prosecution process. With 562 resolved cases, the data highlights that while the allowance rate is moderate, the 60.8 percent interview lift offers a strong pathway to overcoming rejections. The 1364-day median should be factored into the overall prosecution strategy for this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18023256 | METHOD FOR PRODUCING BIOMASS COMPRISING PROTEIN AND OMEGA-3 FATTY ACIDS FROM SINGLE MICROALGAE, AND BIOMASS PRODUCED THEREBY | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18033903 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17757528 | SORBITAN ESTERS AND PROCESS FOR ENZYMATICALLY PREPARING SAME | Final Rejection | Evonik Operations GmbH |
| 17565834 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS | Final Rejection | Cedars-Sinai Medical Center |
| 18908355 | FLUORESCENCE DETECTION OF PERFLUOROALKYL SUBSTANCES USING LIVING CULTURES OF A NEWLY ISOLATED PSEUDOMONAS SP. BACTERIUM | Non-Final OA | The Government of the United States of America, as represented by the Secretary of the Navy |
| 18863122 | PEST CONTROL COMPOSITIONS | Non-Final OA | Rohm and Haas Company |
| 18539656 | COMPOSITIONS AND METHODS FOR IMPROVING THE HEALTH OF AQUATIC ANIMALS | Non-Final OA | Novozymes A/S |
| 18728307 | Streptococcus thermophilus Strains with Improved Texturing Properties | Non-Final OA | Chr. Hansen A/S |
| 18824184 | METHODS FOR TREATING POLYMICROBIAL INFECTIONS | Non-Final OA | CAP Diagnostics, LLC dba Pathnostics |
| 17104593 | PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | Final Rejection | Genzyme Corporation |
| 18679622 | SYSTEM AND METHOD FOR METHANE BIODEGRADATION | Non-Final OA | Parsons Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy